Sanofi's Genetic Disorder Drug Shows Promise in Gaucher Trial, Stumbles in Fabry Study
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.